<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335827</url>
  </required_header>
  <id_info>
    <org_study_id>IRE-001</org_study_id>
    <nct_id>NCT02335827</nct_id>
  </id_info>
  <brief_title>Irreversible Electroporation(IRE) For Unresectable Renal Tumors</brief_title>
  <acronym>IRE</acronym>
  <official_title>Irreversible Electroporation (IRE) for Unresectable Renal Tumors: Phase I and Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of irreversible&#xD;
      electroporation (IRE) for unresectable renal tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By enrolling patients with renal tumors adapted to enrolled criteria, this study will&#xD;
      document for the first time the safety and the short and long term efficacy of percutaneous&#xD;
      or intraoperative IRE for renal tumors .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse effects</measure>
    <time_frame>1 month</time_frame>
    <description>adverse effects measured by such as abdominal bleeding, continuous abdominal pain, renal failure, et al.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>2 months</time_frame>
    <description>Quality of Life assessed as WHOQOL-BREF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>procedural compliance</measure>
    <time_frame>3 months</time_frame>
    <description>compliance will be analyzed by 3 months of follow-up post procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>12 months</time_frame>
    <description>efficacy assessment by percentage of lesions that show no sign of recurrence 12 months after the initial IRE procedure) of IRE for renal tumor via cross-sectional imaging and pathological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voltage (A minimum and maximum range of voltage for safe and effective IRE)</measure>
    <time_frame>3 months</time_frame>
    <description>A minimum and maximum range of voltage for safe and effective IRE will be analyzed for optimal choice.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progress free disease (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will be followed for 12 months after IRE for PFS assessing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Patients will be followed for 36 months after IRE for OS analyzed.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Renal Tumor</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irreversible electroporation with voltage in level A for renal tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irreversible electroporation with voltage in level B for renal tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irreversible electroporation with voltage in level C for renal tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>irreversible electroporation</intervention_name>
    <description>Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  unresectable kidney tumors&#xD;
&#xD;
          -  patients refused surgical therapy&#xD;
&#xD;
          -  Karnofsky-index &gt;70%&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 80 years&#xD;
&#xD;
          -  life expectancy ≥ 12 month&#xD;
&#xD;
          -  compliance of the patient taking part in a study&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  violation against one or more inclusion criteria&#xD;
&#xD;
          -  an estimated glomerular filtration rate (eGFR) of &lt; 30 mL/min/1.73 m2&#xD;
&#xD;
          -  QT-interval &gt;550 ms or cardiac arrhythmias or condition after myocardial infarction,&#xD;
             that make an ECG-synchronisation unfeasible&#xD;
&#xD;
          -  active infection or severe health interference, that make taking part in a study&#xD;
             unfeasible&#xD;
&#xD;
          -  pregnancy, lactation period&#xD;
&#xD;
          -  general contraindications for anesthesia, endotracheal anesthesia and muscle&#xD;
             relaxation&#xD;
&#xD;
          -  psychiatric disorders that make taking part in a study or giving informed consent&#xD;
             unfeasible&#xD;
&#xD;
          -  haemorrhage, impossible intermission of taking blood thinner, untreatable&#xD;
             thrombophilia&#xD;
&#xD;
          -  thromboplastin time ≤50 %, thrombocytes ≤50 Gpt/L; partial thromboplastin time &gt;50&#xD;
&#xD;
          -  untreated urinary retention&#xD;
&#xD;
          -  severe hepatic dysfunction&#xD;
&#xD;
          -  any other clinically important renal, hematological, metabolic, neurological,&#xD;
             gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study&#xD;
             participation (investigator's assessment)&#xD;
&#xD;
          -  taking part in another clinical study for renal tumor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuda Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510665</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 2, 2015</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irreversible electroporation</keyword>
  <keyword>renal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

